Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | ARG1 | P05089 | 2/20 | 0.40 |
| ▸ | ARG2 | P78540 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.31 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27286922 | 0.84 | GABRR1 (0.52) | GABRR1CYP1A2LTA4HBLMACE2 | |
| SCHEMBL3753790 | 0.84 | GABRR1 (0.52) | GABRR1CYP1A2LTA4HBLMACE2 | |
| SCHEMBL28466762 | 0.82 | GABRR1 (0.50) | GABRR1CYP1A2LTA4HBLMACE2 | |
| SCHEMBL1818554 | 0.82 | GGT1 (0.58) | GGT1ARG1ARG2CYP1A2BLM | |
| Hydrochloric Acid SCHEMBL31156457 | 0.80 | GGT1 (0.56) | GGT1ARG1ARG2CYP1A2BLM | |
| SCHEMBL8687592 | 0.76 | GGT1 (0.65) | GGT1ARG1ARG2CYP1A2BLM | |
| SCHEMBL20825612 | 0.74 | BLM (0.54) | GABRR1CYP1A2LTA4HBLMACE2 | |
| SCHEMBL8827662 | 0.73 | GABRR1 (0.56) | GABRR1GGT1ARG1ARG2CYP1A2 | |
| SCHEMBL10443300 | 0.72 | GABRR1 (0.43) | GABRR1GGT1ARG1ARG2CYP1A2 | |
| SCHEMBL1300782 | 0.72 | GABRR1 (0.43) | GABRR1GGT1ARG1ARG2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, OPRD1 | GABRR1 648/4885GGT1 1354/4885ARG1 655/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | GABRR1 1069/4885GGT1 1665/4885ARG1 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.